- Athenex ( NASDAQ: ATNX ) plunged 23.9% down premarket after it priced its underwritten public offering of 35.3M shares and accompanying warrants at a combined public offering price of $0.75/share and accompanying warrant, pre-funded warrants to purchase up to 4.67M shares at a combined public offering price of $0.749/share and accompanying warrant.
- Gross proceeds are expected to be ~$30M.
- Offer is expected to close on Aug.15, 2022.
- Net proceeds was used to fund ongoing clinical development for its product candidates and for working capital and other general corporate purposes.
For further details see:
Athenex prices $30M in stock and warrants offering